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Abstract
Background: Cancer prevention trials using different types of antioxidant supplements have been
carried out at several occasions and one of the investigated compounds has been the antioxidant
N-acetyl-L-cysteine (NAC). Studies at the cellular level have previously demonstrated that a single
supplementation of NAC induces a ten-fold more rapid differentiation in normal primary human
keratinocytes as well as a reversion of a colon carcinoma cell line from neoplastic proliferation to
apical-basolateral differentiation [1]. The investigated cells showed an early change in the
organization of the cytoskeleton, several newly established adherens junctions with E-cadherin/β -
catenin complexes and increased focal adhesions, all features characterizing the differentiation
process.
Methods: In order to investigate the molecular mechanisms underlying the proliferation arrest and
accelerated differentiation induced by NAC treatment of NHEK and Caco-2 cells in vitro, we
performed global gene expression analysis of NAC treated cells in a time series (1, 12 and 24 hours
post NAC treatment) using the Affymetrix GeneChip™ Human Genome U95Av2 chip, which
contains approximately 12,000 previously characterized sequences. The treated samples were
compared to the corresponding untreated culture at the same time point.
Results:  Microarray data analysis revealed an increasing number of differentially expressed
transcripts over time upon NAC treatment. The early response (1 hour) was transient, while a
constitutive trend was commonly found among genes differentially regulated at later time points
(12 and 24 hours). Connections to the induction of differentiation and inhibition of growth were
identified for a majority of up- and down-regulated genes. All of the observed transcriptional
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changes, except for seven genes, were unique to either cell line. Only one gene, ID-1, was mutually
regulated at 1 hour post treatment and might represent a common mediator of early NAC action.
The detection of several genes that previously have been identified as stimulated or repressed
during the differentiation of NHEK and Caco-2 provided validation of results. In addition, real-time
kinetic PCR analysis of selected genes also verified the differential regulation as identified by the
microarray platform.
Conclusion: NAC induces a limited and transient early response followed by a more consistent
and extensively different expression at later time points in both the normal and cancer cell lines
investigated. The responses are largely related to inhibition of proliferation and stimulation of
differentiation in both cell types but are almost completely lineage specific. ID-1 is indicated as an
early mediator of NAC action.
Background
Most human cancers arise in epithelial cells, underlining
the importance of understanding the molecular biology of
cancer and the complex balance of proliferation and dif-
ferentiation in this cell type. Increased knowledge of these
processes may provide unique targets for the future devel-
opment of pharmacotherapy aiming at halting or revers-
ing metastasis and cancer growth.
N-acetyl-L-cysteine (NAC) is a membrane permeable ami-
nothiol that functions as a nucleophilic ROS scavenger
and antioxidant as well as a precursor of intracellular
cysteine and glutathione (GSH). The reduced cysteine rep-
resents the active form, as opposed to the inactive oxi-
dized cystine dimer. To date, NAC is used as a mucolytic
and as acute treatment of fulminant hepatic failure fol-
lowing paracetamol poisoning. However, cancer prevent-
ing and therapeutic effects have also been suggested. In
particular, NAC has been demonstrated to induce anti-
proliferative and differentiating effects in normal human
epidermal keratinocytes (NHEK), as well as in the epithe-
lial colon cancer cell line Caco-2 [1]. Primary normal
human epidermal keratinocytes (NHEK) undergo sponta-
neous terminal differentiation over 30 days in culture.
However, if supplemented with 2 mM NAC 24 hrs after
seeding, an accelerated differentiation process can be
observed. Three days post NAC exposure, differentiation
of NHEK is demonstrated by an increased number of
intercellular junctions, basal localization of cytokeratin
and apical localization of actin determined by scanning
electron micrographs of cells and sub-structures and high
resolution confocal fluorescence immuno micrographs of
for example β -catenin, E-cadherin, actin and cytokeratins.
Furthermore ceased proliferation can be demonstrated by
3H thymidine incorporation without accompanying
apoptosis experimentally verified by properdium iodide
labelling and flow cytometry. Interestingly, an epithelial
colon cancer cell line responded in analogy with the nor-
mal epithelial cells. Caco-2 differentiate spontaneously
over a period of around 25–30 days in culture [2]. How-
ever, when a single supplement of 10 mM NAC was given
to Caco-2 cells 24 hrs after seeding, the proliferation
decreased and the cells progressed to a differentiated state
in three days without any sign of apoptosis [1]. Here the
differences in gene expression was studied overtime for
both NHEK and Caco-2 cells using microarray technology
with subsequent confirmation of a selected set of genes.
The results are discussed from the perspective of acceler-
ated differentiation and growth arrest.
Methods
Cell cultures
Normal human epidermal keratinocytes, NHEK (Cam-
brex, San Diego, CA), plated at a density of 8 × 103 cells/
cm2, were grown in KGM®  medium plus KGM®  Sin-
gleQuots® (Cambrex). The Caco-2 human colon carci-
noma cells were seeded at a density of 9 × 103 cells/cm2,
grown in Dulbecco's modified Eagle minimum essential
medium (DMEM, GIBCO Labs, Grand Island, N.Y.), sup-
plemented with 10% (v/v) heat-inactivated fetal calf
serum (GIBCO Labs), L-glutamine (2 mM), penicillin (50
IU/ml) and streptomycin (50 mg/ml). The N-acetyl-L-
cysteine (NAC, Sigma Chem. Co., St Louis, MO) stock
solution (20 mM in KGM and 100 mM in DMEM) was
stored at 4°C in the dark and used within 1 week from
preparation. Twenty-four hrs after seeding, filter sterilized
NAC solution was added to the cell cultures to a final con-
centration of 2 mM and 10 mM in NHEK and Caco-2
respectively. The concentrations were selected after per-
forming a dose-dependent inhibition analysis for each of
the two cell types [1].
Scanning electron microscopy
Cells grown on coverslips were fixed with 2.5% glutharal-
dehyde in 0.1 M Millonig's phosphate buffer (MPB) at
4°C for 1 hr. After washing in MPB, cells were post-fixed
with 1% OsO4 in the same buffer for 1 hr at 4°C and dehy-
drated in increasing acetone concentrations. The speci-
mens were critical-point dried using liquid CO2  and
sputter-coated with gold before examination on aBMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Stereoscan 240 scanning electron microscope (Cambridge
Instr., Cambridge, UK).
Experimental set up
From the normal (NHEK) cells, RNA was obtained from
cultures grown for 1, 12 and 24 hrs after NAC treatment
as well as from untreated cells at the same time points.
Replicates at the level of individually performed cDNA
synthesis were used for hybridisation in duplicate for the
1, 12 and 24 h time points except for one fall out of a 24
hrs post NAC treated sample. RNA was extracted from
both treated and non-treated cancer (Caco-2) cell cultures
at 1, 12 and 24 hrs. Biological replicates were used for
hybridisation in a duplicate fashion for both treated and
non-treated samples.
RNA extraction, purification and quality control
The total RNA was extracted from cell cultures using Trizol
(Gibco BRL, NY, USA) according to the manufacturers
instructions. Thereafter mRNA was extracted by oligo dT
Dynabeads (Dynal, Oslo, Norway) and the quality of
mRNA was validated using the Bioanalyzer 2100 (Agilent
technologies, Waldbrunn, Germany).
Target preparation and hybridisation
A total of 8 micrograms of mRNA from each sample was
used to perform cDNA synthesis. Following in vitro tran-
scription, the biotin labelled cRNA was fragmented and a
total of 15 micrograms were subsequently hybridised and
analysed on the Affymetrix GeneChip™, all according to
the manufacturers instructions (Affymetrix, Santa Clara,
USA) with scanning performed on the GeneArray 2500A
Scanner (Affymetrix, Santa Clara, USA).
Data analysis
The MAS 5.0 software package (Affymetrix Inc.) was used
to compute cell intensity files (.cel) for each chip. For the
purpose of inspection of parameters important to quality
control, chip files (.chp) were also generated for each chip
using the statistical expression algorithm. Next, individual
probeset intensity values were computed based on the cell
intensity files using the RMA algorithm within the Biocon-
ductor package. All data was analysed in three separate
batches (2 separate sample preparation batches for the
Caco-2 cell line and one for NHEK cell line. Each batch
also included RNA samples obtained from 30 min, 3 hrs
and 48 hrs treated and untreated cell cultures which are
not presented in this manuscript). The RMA background
correction, quantile normalization, only PM probe correc-
tion and a median polishing were applied. Next, data
probeset intensities from each sample were converted to a
biological fold ratio between the treated and control sam-
ple. To generate the ratio, signal intensities of each treated
sample were divided by the control sample intensities for
each corresponding time point, separately within each
RMA batch. Because of a missing 24 hrs control for NHEK
cell line due to fallout, time point 12 hrs control was used
instead (detailed investigation showed that control sam-
ples at each time point were extremely similar to each
other, rationalizing this choice). The average of replicates
for each time point in two cell lines was used in the down-
stream analysis. Due to the quality control issues encoun-
tered with time point 24 hrs NHEK cell line, only one
replicate was used. The standard deviation statistics was
calculated using the Global Error Model based on devia-
tion from one (GeneSpring, Silicon Genetics). A final total
of 6 conditions were generated (1, 12, 24 hrs time points
for NHEK and Caco-2). The MIAME compatible dataset is
made available at the ArrayExpress expression data repos-
itory at EMBL.
In order to identify genes that show significant changes
during treatment we searched for genes that show signifi-
cant up- or down-regulation in treatment relative to the
control, in at least one of the time point for one of the cell
lines (filtering was done using the t-test p-value < 0.01,
indicating significant deviation from the control value or
from the ratio of 1). Two-way hierarchical clustering of
genes and conditions was performed using the set of pre-
filtered genes (2054) and Standard correlation. In order to
identify genes with significant NAC treatment response at
each time point for each cell line we applied a two-step fil-
tering based on the t-test p-value of less than 0.1 (indicat-
ing statistically significant changes from the control
value), and a biological fold cut-off of 1.5 fold (up or
down). A total of 6 genelists (3 for each cell line) was pro-
duced and visualized graphically for common distinct
patterns. Data filtering and visualization was performed
using GeneSpring (Silicon Genetics). To assess the over-
representation of functional groups, according to Gene
Ontology, the publicly available tool EASE (v2.0) was
used [3].
Real-time kinetic PCR
Validation of microarray results was performed by quanti-
fying relative mRNA expression levels of several genes of
interest. Two RT-PCR formats were used for the investi-
gated genes. The first relied on primers and TaqMan
probes obtained from Applied Biosystems and their
Assay-on-demand system and the second approach was
based on in-house designed primers and SYBR green
detection. The assays used either the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) or the transferrin
receptor (TFR) as the endogenous internal reference gene.
For the first method, cDNA synthesis was performed using
SuperScript™ III (Invitrogen) in a 20 µl reaction contain-
ing: 1x first strand buffer, 5 mM DDT, 40 U RNasin
(Promega), 5 µg total RNA, 200 U SuperScript™ III, 250
mM oligo(dT)20 primer, 0,5 mM dNTP each dATP, dGTP,BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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dCTP, dTTP. Primer, total RNA and nucleotides were
heated to 65°C for 5 min and subsequently cooled on ice
for 1 min. After addition of the other reagents the samples
were incubated at 50°C for approximately 60 min.
Finally, the reaction was inactivated by heating to 70°C
for 15 min. Assays-on-Demand (Applied Biosystems),
containing gene specific primers and probes labelled with
6-carboxyfluorescein (FAM) at the 5' end and with 6-car-
boxytetramethylrhodamine (TAMRA) at the 3' end for the
following genes: GAPDH  (Genbank nb. BC029618),
MMP9 (J05070), AKR1C3  (D17793), AQP3  (N74607),
PLAT (M15518), HBP1 (AF019214), PTGS2 (U04636),
ERBB3 (M34309) and PNRC1 (U03105) (see Table 3),
were used together with TaqMan Universal PCR Master
Mix (Applied Biosystems) in the TaqMan real time PCR
reaction as described by the manufacturer. 25 µl reactions
were done in 96-well plates. Amplification and detection
was carried out using the iCycler iQ Multicolor Real-Time
PCR Detection System (Bio-Rad Laboratories, Hercules,
CA, USA). All samples were run in triplicate.
For the second method, in-house designed gene-specific
primers for six human transcripts (Transferrin receptor
(TFR): NM_003234 (5'-TCCCTAGGAGGCCGTTTCC-
3'and 5'-GCCTACCCATTCGTGGTGAT-3), COX-2:
NM_000963 (5'-GCATTGGAAACATCGACAGTGT-3'and
5'-TGACGTCTTTTTACTTGAATTTCAACTTATAT-3);
NDRG1: NM_006096 (5'-CCAGTGCGGCTGCCAG-3'and
5'-TTCCTATGAGAAAATCCACGGTG-3);  TP53:
NM_000546 (5'-CCTTGAGGGTGCCTGTTCC-3'and 5'-
CCCTCTACCTAACCAGCTGCC-3');CDH1: NM_004360
('5'-TGAAGACCTTTAATGGCTTCCC-3'and 5'-CACACT-
TACTCAGAACAAGTCACTGG-3'); HSPB1: NM_001540)
(5'-AAAATCCGATGAGACTGCCG-3' and 5'-
GCACAGCCAGTGGCGG-3') were designed using the
Primer Express software (Applied Biosystems, Foster City,
CA, USA). Real time RT-PCR analysis was performed in
triplicate using ds cDNA synthesized from mRNA
obtained from the investigated cells. All PCRs were per-
formed at 60°C annealing temperature and the TFR gene
was used as internal standard. A PCR mastermixture was
prepared using the SYBRGreen PCR Core Reagents
(Applied Biosystems, Foster City, USA) and aliquoted into
microplate wells together with 1 µl template and 5 pmol
of each primer for a final volume of 25 µl per reaction. The
iCycler (Bio-Rad) was used for PCR and detection of fluo-
rescent signals. Standard curves (CT versus log concentra-
tion) were generated for each primer pair using duplicate
cDNA samples in a series of consecutive 5-fold dilutions.
Efficiency calculations (E=(10^(-1/amplificationslope)-
1) were performed to validate compatibility of investi-
gated genes with the internal control. The compatibility of
all pair-wise compared amplification efficiencies were
confirmed with a maximal deviation of 10% (data not
shown). The specificity of all individual amplification
reactions was confirmed by meltcurve analysis (data not
shown).
The relative mRNA expression levels of the target genes in
each sample were calculated using the comparative CT
method. The CT value was defined as the number of PCR
cycles required for the fluorescence signal to exceed the
threshold value. CT values were defined as the absolute
value of the difference between the CT of the target RNA
and the Ct of the housekeeping gene RNA for each sam-
ple. The level of significance was set to a 2-fold relative dif-
ference between samples, i.e. significant fold change 0.5 <
2-∆∆ C
T > 2 for down- and up-regulated genes respectively.
Results
Experimental overview
The aim of this work was to study the molecular effects of
the antioxidant N-actetyl- cysteine (NAC) on proliferating
cells, by gene expression analysis using the Affymetrix
GeneChip platform. Previous studies on cell culture sys-
tems, demonstrated mainly by morphological and bio-
chemical data, have indicated that NAC addition
stimulates proliferating cells to go into differentiation
phase [1]. Figure 1 displays a scanning electro micrograph
image of the cell types tested and demonstrates the mor-
phological shift from proliferating to differentiating cells
after addition of NAC. We have performed a microarray-
based gene expression analysis of the human colon carci-
noma cell line (Caco-2) and normal human epidermal
keratinocytes (NHEK) over time (1, 12, and 24 hrs) after
addition of NAC, compared to untreated, control samples
at the same time points. Data obtained from GeneChip
analysis were processed using the RMA analysis approach
and samples were normalized to their corresponding con-
trols. Filtering was done based on two criteria (p-value <
0.1 and >1.5 fold up-or down-regulation) for each time
point. The labelling and hybridisation was done in dupli-
cate, except at 24 hrs NAC treatment of NHEK, where a
single measurement was made.
Analysis
Gene lists of up- and down-regulated genes at each time
point for NHEK and Caco-2 (1, 12, 24 hrs) were gener-
Table 1: Number of genes induced/repressed at each time point.
Time points Caco-2 NHEK
1 hr (repressed) 8 16
12 hrs (repressed) 54 10
24 hrs (repressed) 86 171
1 hrs (induced) 1 26
12 hrs (induced) 69 28
24 hrs (induced) 35 163BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Scanning electron micrographs showing the effect of NAC treatment on the morphology of NHEK (A) and Caco-2 (B) cells Figure 1
Scanning electron micrographs showing the effect of NAC treatment on the morphology of NHEK (A) and 
Caco-2 (B) cells. A1) NHEK untreated controls show a heterogeneous polygonal morphology, with a villous surface and rel-
atively broad intercellular space; A2) After 72 h with 2 mM NAC cells grow flat in a thin monolayer with a regular polygonal 
morphology and a smooth surface with loss of the fine microvillous structure, also showing dramatically reduced intercellular 
space. B1) Proliferating Caco-2 cells display an irregular morphology with scarce microvillous structures and large intercellular 
space; B2) After 72 h with 2 mM NAC Caco-2 cells had the morphology of end-stage differentiated cells, with a regularly polyg-
onal and about three times thicker than controls, with a relevant number of brush border microvilli at the cell surface (black 
arrows) as well as a dramatically reduced intercellular space (white arrows). Bars: 20 µmBMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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ated. In addition, time points within each cell type were
analysed to identify similarities/differences among early
and late time-point responses. Any results that produced
zero genes were skipped. A summary of the top ten differ-
entially expressed genes in Caco-2 and NHEK, at all time
points, is depicted in additional files 1 and 2. The com-
plete lists of differentially expressed genes are accessible as
additional datafiles 3 and 4 or at http://biobase.bio
tech.kth.se/NACmicroarray.
There were no general differences in the number of tran-
scripts detected in treated as compared to untreated sam-
ples in any of the cell lines. Following NAC induced
differentiation in Caco-2 and NHEK, 253 and 414 targets,
respectively, were significantly differentially expressed
across the time series, according to above statistical crite-
ria (Table 1). Generally, for both cell types, the amount of
significantly up/down-regulated genes is limited to < 200
genes after consideration of multiple appearances. In
Caco-2, a tendency towards more down-regulated genes
was identified, while in NHEK, the numbers of genes
induced was approximately equal to those repressed
(Table 1).
Both Caco-2 and NHEK exhibit a relatively limited early
response at 1 hr, followed by an increasingly stronger
response at 12 and 24 hrs. The initial response could be
characterized as transient, since most of the genes
induced/repressed initially either changed in the opposite
direction later on, or simply went back to normal expres-
sion levels.
The induced/repressed genes in the two cell types are gen-
erally quite different despite their morphological similar-
ities after NAC treatment. This is for example
demonstrated in that most of the genes induced/repressed
in Caco-2 show no change in expression levels in NHEK
and vice versa (see below). A direct comparison of the cor-
responding differentially expressed genes is also provided.
Caco-2 analysis
The general trends for Caco-2 cells are depicted in Figure
2 based on the collection of genes that passed the set
criteria.
The graph shows the behaviour of genes induced/
repressed in Caco-2 across the time courses in both cell
types (signal represents the fold difference between each
treatment and the average of corresponding controls). As
indicated above, there is a small transient change at 1 hr,
and a more significant change, taking place at later time
points. In particular, it is observed that the majority of
genes repressed at 12 hrs continue their trend at 24 hrs
(blue lines correspond to 12 hrs genes, dark green line cor-
responds to 24 hrs genes only). Similarly, many genes up-
regulated at 12 hrs continue the trend at 24 hrs (red line
12 hrs genes, orange line 24 hrs genes only). (Gene lists
showing multiple appearances in the same cell type, Caco-
2, at more than one time point can be found in additional
file 4 or at http://biobase.biotech.kth.se/NACmicroarray).
The expression pattern of the corresponding genes in the
other cell system NHEK shows weak or no correlation.
Table 1 represents the number of genes induced/repressed
at each time point for Caco-2 cells and NHEK cells,
including those with changes across multiple time points.
Again, it is evident that early activity (1 hr) is limited and
quite different from the activity at later time points and
that few genes induced/repressed early on (1 hr) continue
their trend at later time points (Figure 2). This has also
been observed after 24 and 48 hrs using another microar-
ray platform based on spotted cDNA arrays (data not
shown).
NHEK analysis
The NHEK cells were analysed in a similar manner (see
additional file 3 or http://biobase.biotech.kth.se/NAC
microarray). The t-test p-value for NHEK 24 hrs is not
included, since there were no treatment replicates; an
error model was used instead. However, some of the val-
ues in the error model do not correspond, in this case, to
other t-test p-values and are therefore not included.
A similar trend to that described for Caco-2 takes place in
these cells, with early transient response at 1 hr, followed
by a more extensive response at later time points (12, 24
hrs) as demonstrated in Figure 3. Again, the genes active
at 1 hr do not appear to be active at later time points
(except for a few genes in each case). On the other hand,
genes active at 12 hrs also appear active in the same direc-
tion at 24 hrs. Table 1 includes the exact numbers of
induced/repressed genes.
NHEK vs. Caco-2 analysis
Comparisons of NAC treated Caco-2 and NHEK show that
the responses are very different. Only a few genes were reg-
ulated similarly in both cells (Table 2).
Even if we consider that statistical considerations (filter-
ing etc.) inaccurately prevented a number of genes from
overlapping in analysis of two cells, the clustering in Fig-
ure 4 show that the responses are indeed very different.
The hierarchical clustering is based on filtered genes (sig-
nificant change in at least one time point) for all time
points and each cell type. At the time point 1 h after treat-
ment, there is no cell-specific clustering. Actually, both
cell types are in the same cluster for 1 hr. It is in the later
time points, with much stronger and distinct response,
that the cell-specific clusters form (blue = NHEK, green =
Caco-2).BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Matrix view of significantly affected genes Figure 2
Matrix view of significantly affected genes. Genes induced/repressed in Caco-2 relative to control and their correspond-
ing expression profiles in NHEK. The color is specific for genelist of affected genes at each time point (unless these are the 
same genes as from one of the earlier time points). Clearly, the early response at 1 hr is very limited (1,8 genes in Caco-2). 
There are also almost no genes induced/repressed at 1 hr that continue the trend at later time points – indicating an early tran-
sient response. This is markedly different for 12 hr and 24 hr time points that show many common genes. It is also clear that 
many genes affected by NAC treatment in one cell line don't show the same response in the other cell line.BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Matrix view of significantly affected genes Figure 3
Matrix view of significantly affected genes. Genes induced/repressed in NHEK relative to control. The color is specific 
for genelist of affected genes at each time point (unless these are the same genes as from one of the earlier time points). Also 
in these cells, quite a limited early response is observed at 1 hr (16 and 26 genes in NHEK). There are almost no genes 
induced/repressed at 1 hr that continue the trend at later time points -indicating an early transient response. This is markedly 
different for 12 hrs and 24 hrs treatments that show many common genes. It is also clear that many genes affected by NAC 
treatment in one cell line don't show the same response in the other cell line.BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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A set of genes indicated to be differentially expressed were
chosen to validate the analysis (Table 3). Additional time
points were also used in this analysis. The genes repre-
sented both markers of proliferation and motility as well
as new candidates in these and other related processes and
in many of these cases the differential gene expression
could be confirmed.
Gene ontology analysis of Caco-2 and NHEK
In order to perform Gene Ontology analysis of signifi-
cantly regulated genes in Caco-2 and NHEK we created
combined lists of genes up- and down-regulated at any of
the three time points. In order to statistically assess the
overrepresentation of each category we used the publicly
available tool EASE. For each cell line, the down-regulated
genes were assessed for gene ontology enrichment relative
to the up-regulated genes in the same cell line, within the
universe of all genes being the Affymetrix U95aVer2 probe
set. The final table of gene ontology groups was selected
based on the number of overlapping genes, EASE score,
illustrating common biological mechanisms or pathways
(e.g. motility, cell division).
The results of analysis in both cell lines indicate a strong
tendency towards differentiation by halting cell prolifera-
tion and related processes, Table 4 (NHEK) and Table 5
(Caco-2). However, the mechanisms inhibiting cell prolif-
eration in NHEK and Caco-2 cell lines appear to differ
significantly. As seen from the two tables, genes responsi-
ble for proliferation are shut down in both cell lines, with
NHEK showing a stronger direct proliferation effect (more
genes are shut down). This effect, however, can be
explained by a considerably higher number of
significantly regulated genes identified in NHEK vs. Caco-
2. Furthermore, the mechanism of inhibiting prolifera-
tion in NHEK appears to be directly related to the shut
down of processes such as nuclear division, mitosis, cyto-
kinesis etc. – all required for cells to divide and proliferate.
In Caco-2, on the other hand, the mechanism appears to
involve cell structure inhibition, through the shut down
of genes involved in adhesion and cytoskeleton changes.
Finally, the motility processes critical to Caco-2 inhibition
of proliferation are affected in NHEK, while cell division
seems to be affected to a lesser degree in Caco-2.
Discussion
Deregulation of proliferation is a characteristic of tumori-
genesis and therapeutic approaches for cancer treatment
targets apoptosis, cell cycle arrest and differentiation. NAC
has been shown to induce a multitude of molecular
changes related to tumorigenesis [4]. Recently, NAC has
been demonstrated to inhibit apoptosis [5,6], possess
anti-inflammatory activities [7] and inhibit proliferation
[8].
Here, we have monitored the reflection in global gene
expression profiles of the transition from proliferation to
a differentiated state in normal and cancer cells in vitro, as
induced by NAC. Two out of three previous studies of the
global gene expression that accompanies the spontaneous
differentiation of Caco-2 report a general down-regula-
tion of gene expression in differentiated cells as compared
to the proliferating counterpart [9-11]. A similar, but not
as pronounced, trend is reflected in the number of genes
differentially expressed following NAC induced differenti-
ation in Caco-2.
The expression level of 253 targets in Caco-2 and 414 in
NHEK were statistically differentially expressed at differ-
ent time points. Multiple appearances of differentially reg-
ulated transcripts were common, resulting in detection of
totally less than 200 unique genes, respectively. This is
fewer than expected in comparison to previous reports on
differential regulation during spontaneous Caco-2
differentiation and probably due to the difference in strin-
gency of the algorithms used for data analyses (MAS 4.0 vs
RMA), rather than related to functional biological
discrepancies.
Initial response
In both data sets, the early responses were relatively lim-
ited and appeared to be transient, indicating that a large
Table 2: Genes common in both Caco-2 and NHEK at the different time points.
Time point Regulation Probe ID Gene
1 hr repressed 36618_g_at Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein
12 hrs repressed none
24 hrs repressed 33720_at 1069_at Putatative 28 kDa protein, Human cyclooxygenase-2 (hCox-2) gene, complete cds
1 hr induced none
12 hrs induced 39809_at 36980_at 1585_at HMG-box transcription factor 1 proline-rich nuclear receptor coactivator 1 v-erb-b2 
erythroblastic leukemia viral oncogene homolog 3 (avian)
24hrs induced 39248_at Aquaporin 3BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Hierarchical clustering diagram at 1, 12 and 24 hrs Figure 4
Hierarchical clustering diagram at 1, 12 and 24 hrs. A set of 2054 genes which show significant changes in expression in 
at least one of the time points in either of the two cell line clustered using the standard correlation. Cluster of the correspond-
ing time points for each cell line indicates very close similarity of NHEK and Caco-2 at time point 1 hr, at which the NAC effect 
is not yet pronounced (both cell lines form a tight separate cluster at 1 hr). However, during the later time points the changes 
are much more significant and the differences between Caco-2 and NHEK become very pronounced as well (each cell line 
forms a separate cluster that includes both 12 and 24 hrs time points).BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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part of initial immediate early events occur at the level of
translation and post-translational modifications. The
nature of initial regulatory events is also expected to be
transient due to feedback inhibition as well as to a
restricted number of NAC induced mechanisms.
Interestingly, significant transcriptional down-regulation
of the inhibitor of differentiation 1 (ID-1) was found at 1 hr
in both Caco-2 and NHEK, suggesting a common mecha-
nism of NAC induced differentiation and inhibition of
proliferation in NHEK and Caco-2 epithelial cells.
Analysis of ID-1 expression levels by real-time quantita-
tive PCR confirmed the suppression of the transcript in
both cell types (Table 3). ID-1 has been demonstrated to
bind helix-loop helix transcription factors, preventing
them from binding DNA [12]. In particular, ID-1 has been
shown to be required for G1 progression, and its constitu-
tive expression inhibited the lineage commitment and dif-
ferentiation in B-cells [13,14]. Previous reports have also
shown that ID-1 is a negative transcriptional regulator of
Table 3: Relative gene expression levels measured by real time kinetic PCR in Caco-2 and NHEK cells after NAC treatment as 
compared to untreated cells.
Caco-2
Gene Common Genbank 1h 12h 24h 48h
RT-PCR Affymetrix RT-PCR Affymetrix RT-PCR Affymetrix RT-PCR Affymetrix
matrix 
metalloproteinase 9*
MMP9 J05070 na nd no change up na up na na
aldo-keto reductase* AKR1C3 D17793 na nd no change up up (2.8) nd na na
aquaporin 3* AQP3 N74607 no change down up (6.8) up up (5.0) up na na
plasminogen activator, 
tissue*
PLAT M15518 na nd no change nd no change nd na na
HMG-box 
transcription factor 1*
HBP1 AF019214 no change nd up (2.6) up up (2.1) nd na na
Cox-2* PTGS2 U04636 no change nd no change nd down (2.2) down na na
v-erb-b2* ERBB3 M34309 na nd up (3.7) up no change nd na na
proline-rich nuclear 
receptor coactivator 
1*
PNRC1 U03105 na nd no change up up (2.4) nd na na
inhibitor of 
differentiation*
ID1 AA457158 down (3.8) down na nd na nd na nd
E-cadherin** CDH1 Z13009 na nd no change nd up nd no change na
hsp27** HSPB1 U90906 na nd up nd up nd no change na
p53** TP53 U94788 na nd up nd no change nd no change na
N-myc downstream 
regulated gene 1**
NDRG1 D87953 na nd up nd up up up na
NHEK
30 min 3h 12h 24h 48h
Gene Common Genbank RT-PCR Affymetrix 1 h RT-PCR Affymetrix RT-PCR Affymetrix RT-PCR Affymetrix RT-PCR Affymetrix
matrix 
metalloproteinase 9*
MMP9 J05070 no change nd no change nd na up na up up (11.1) nd
aldo-keto reductase* AKR1C3 D17793 na nd down (4.0) nd na nd na nd down (5.3) nd
aquaporin 3* AQP3 N74607 no change nd no change nd na nd na up up (2.8) nd
plasminogen activator, 
tissue*
PLAT M15518 no change nd no change nd na nd na down no change nd
HMG-box 
transcription factor 1*
HBP1 AF019214 down (6.3) nd down (4.0) nd na up na nd no change nd
Cox-2* PTGS2 U04636 down (7.7) nd down (6.3) nd na nd na down down (8.3) nd
v-erb-b2* ERBB3 M34309 na nd down (2.4) nd na up na nd down (4.5) nd
proline-rich nuclear 
receptor coactivator 
1*
PNRC1 U03105 na nd down (5.3) nd na up na nd no change nd
inhibitor of 
differentiation*
ID1 AA457158 down (8.3) down na nd na nd na nd na nd
E-cadherin** CDH1 Z13009 na nd na nd no change nd up nd up nd
hsp27** HSPB1 U90906 na nd na nd up nd up nd up nd
p53** TP53 U94788 na nd na nd no change nd up nd up nd
N-myc downstream 
regulated gene 1**
NDRG1 D87953 na nd na nd no change nd no change nd no change nd
Significant fold change: <0.5 for down regulated and >2.0 for up regulated genes, respectively. na = not analysed; nd = no data. * Taqman RT-PCR was 
done on these genes using Assays-on-demand (Applied Biosystems). GAPDH was used as a reference gene. **SYBR green RT-PCR was done on 
these genes using in house designed primers. Transferrin receptor was used as a reference gene.BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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CDKN2A (p16/p14/p19), which induces G1 arrest through
the inhibition of Rb phosphorylation by cdk -4 and -6
[15]. Overexpression of ID-1 was also reported in psori-
atic involved skin [16]. Inhibitors of histone deacetylase
activity are emerging as a potentially important new class
of anticancer agents. The cell cycle blockade and
differentiation caused by such a drug, trichostatin A,
caused decreased levels of ID-1 consistent with cell cycle
senescence and differentiation of A2780 ovarian cancer
cells [17]. Vitamin D is also known to promote differenti-
ation and was shown by others to down-regulate ID-1
through a suppressive vitamin D response sequence in the
5'of the gene [18]. The ID-1 expression is regulated by a
protein complex containing the immediate-early response
gene EGR1 [19].
The growth regulatory properties of EGR1 have been
found to involve coordinated regulation of TGF-β 1 and
fibronectin (FN1). The resulting proteins are secreted and
lead to increased expression of plasminogen activator
inhibitor-1 (PAI1). Both the secreted FN1 and PAI1 func-
tions to enhance cell attachment and normal cell growth
[20]. We detect the induction of both fibronectin and
PAI1 in NHEK cells at both 12 and 24 hrs, suggesting a
role of EGR1 pathways in the NAC mediated mechanism
at least in this cell type.
Table 4: Gene ontology for differentially expressed genes found in NHEK cells
Gene Category Down (genes) Up (genes) Combined list Affy 
probes
EASE score
mitotic cell cycle 41 4 49 1.96E-14
cell cycle 52 12 76 2.03E-12
M phase 22 1 24 7.73E-09
DNA replication and chromosome cycle 22 1 24 7.73E-09
cell proliferation 56 22 100 0.000000024
nuclear division 20 1 22 7.23E-08
M phase of mitotic cell cycle 19 1 21 0.000000217
DNA replication 19 1 21 0.000000217
S phase of mitotic cell cycle 19 1 21 0.000000217
mitosis 19 1 21 0.000000217
DNA metabolism 29 6 41 0.000000403
DNA dependent DNA replication 13 0 13 0.00000641
cytokinesis 12 0 12 0.0000199
metabolism 100 79 256 0.000126
regulation of cell cycle 26 11 48 0.00137
cell growth and/or maintenance 79 62 202 0.00241
nucleobase\, nucleoside\, nucleotide and nucleic acid metabolism 53 36 124 0.00262
biosynthesis 15 5 24 0.00475
protein metabolism 43 29 101 0.00992
physiological process 132 130 389 0.0103
obsolete biological process 17 7 31 0.0125
macromolecule biosynthesis 11 4 18 0.0267
protein modification 22 14 50 0.0639
cytoplasm organization and biogenesis 12 6 23 0.0693
cell organization and biogenesis 17 13 42 0.211
phosphorus metabolism 16 12 40 0.244
phosphate metabolism 16 12 40 0.244
protein amino acid phosphorylation 12 9 30 0.326
phosphorylation 12 10 32 0.424
macromolecule catabolism 10 8 26 0.435
protein catabolism 10 8 26 0.435
proteolysis and peptidolysis 10 8 26 0.435
cell adhesion 41 6 3 6 1
cell motility 2 6 14 0.995
Bold: processes significantly affected in Caco-2 pointing to differentiation
Italicized: processes significantly downregulated in NHEK, pointing to differentiation
Cutoff (EASE score < 5.00E-01)
Cutoff (#overlapping genes > 9, larger than
in Caco-2 due to a large initial list size).BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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Other interesting down-regulated genes at 1 h after NAC
treatment in NHEK included for example regulated in
development and DNA damage response 1 (REDD1), squa-
mous cell carcinoma antigen 1 (SCCA1), highly expressed in
cancer (HEC), s100a9 and kallikrein 7 (also termed stratum
corneum chymotryptic enzyme – SCCE). REDD1 has previ-
ously been shown to be down-regulated in differentiating
primary human keratinocytes and ectopic expression
inhibits in vitro differentiation [21]. The suppression of
SCCA1 has been demonstrated to inhibit tumour growth
[22], HEC expression is increased in tumours [23] and
S100A9 has been found to be up-regulated in psoriasis
patients displaying keratinocyte hyperproliferation and
altered differentiation [24]. SCCE has been suggested to
play a role in desquamation and its up-regulation is asso-
ciated with poor prognosis of ovarian and breast cancer
[25,26]. A number of interesting up-regulated genes, such
as activin A and WEE1, were also identified in NHEK 1 hr
after NAC treatment. Over expression of WEE1 inhibits
cell cycle progression by inactivation of the CDC2/cylin B
complex [27], while activin A is a member of the TGF-β
family of cytokines which is known to promote growth
arrest and differentiation in several tissues including intes-
tinal epithelia [28,29]. In fact it was first identified as a
protein that exhibits a potent differentiation-inducing
activity [30]. In Caco-2, the proto-oncogene fos and the
transcription factor HNF3A, which have been observed to
be amplified in human malignancies [31], was two of the
identified genes being repressed at 1 hr after NAC treat-
ment. A single gene, integrin alpha 2, was found up-regu-
lated at this time-point.
It is clear that these data collectively describe molecular
changes associated with the mediation of a differentiated
Table 5: Gene ontology for differentially expressed genes found in Caco-2 cells
Gene Category Down (genes) Up (genes) Combined list Affy 
probes
EASE score
cell motility 8 1 10 0.0459
cytoplasm organization and biogenesis 8 1 10 0.0459
muscle development 7 1 9 0.0872
morphogenesis 18 7 33 0.0879
development 22 10 43 0.107
cell adhesion 11 3 18 0.112
cell surface receptor linked signal transduction 11 3 18 0.112
organelle organization and biogenesis 6 1 8 0.158
cytoskeleton organization and biogenesis 6 1 8 0.158
cell organization and biogenesis 11 4 19 0.159
organogenesis 16 7 31 0.179
response to stress 8 3 14 0.282
macromolecule biosynthesis 9 4 17 0.331
cell-cell signaling 6 2 10 0.346
signal transduction 19 5 30 0.0118
immune response 9 1 11 0.0233
protein metabolism 15 4 23 0.0235
cellular process 58 34 126 0.0316
defense response 10 2 14 0.0467
transcription\, DNA-dependent 17 10 37 0.358
transcription 17 10 37 0.358
response to biotic stimulus 10 5 20 0.374
nucleobase\, nucleoside\, nucleotide and nucleic acid metabolism 24 16 56 0.434
regulation of transcription\, DNA-dependent 16 10 36 0.442
regulation of transcription 16 10 36 0.442
cell cycle 9 5 19 0.486
nucleotide metabolism 3 2 7 0.835
nuclear division 3 3 9 0.927
mitosis 3 3 9 0.927
mitotic cell cycle 5 3 11 0.691
cytokinesis 2 2 6 0.952
Bold: processes significantly downregulated in NHEK pointing to differentiation
Italicized: specific processes significantly downregulated in Caco-2, pointing to differentiation
Cutoff (EASE score) < 5.00E-01
Cutoff (Number of overlapping genes > 5BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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epithelial phenotype. A large part of the differentially
expressed genes have clear implications in withdrawal of
mitogenic signals and in promotion of growth arrest. Mul-
tiple signalling pathways are suggested to be involved.
Late response (multiple occurrences)
Progressively more genes were affected in both cell types,
and many showed similar trends in direction, over later
time points. Cluster analysis revealed tightly linked genes
between the 12 and 24 hrs time points in the same cell
type and genes with such multiple appearances are poten-
tially more strongly implicated in the differentiation
process.
In NHEK cells, for example the down-regulated mitogens
neuregulin 1 (heregulin) and melanoma growth stimulatory
activity (MGSA) [32], belong to this group. MGSA belongs
to a super family of chemochines, including IL-8, which is
involved in inflammatory processes. Heregulin is known
to activate the oncogenic ERBB2 receptor [33]. Cdc-6,
which are regulated in response to mitogenic signals,
binds PCNA and is required for initiation of DNA replica-
tion [34], was also repressed at both 12 and 24 hrs after
NAC treatment, implying programs involving withdrawal
of mitogenic factors as important mechanisms for NAC
mediated inhibition of proliferation and increased differ-
entiation in NHEK cells. The expression of Topoisomerase II
(TOP2) was also repressed, confirming results obtained in
NAC treated CHO cells [35]. Topoisomerases control and
alter the topologic states of DNA, and the relaxation activ-
ity of TOP2 is essential for productive RNA synthesis on
nucleosomal DNA [36].
The list of correspondingly important up-regulated genes
in NHEK was extensive and included activin A,  trans-
glutaminase 2 (TGM2), ErbB3 (HER3), matrix metalloprotei-
nase 9 (MMP-9), fibronectin (FN!), PAI1 and TGFβ  among
others. Notably, activin A was the only gene found to be
up-regulated at all investigated time points, demonstrat-
ing a sustained growth inhibitory and differentiation pro-
moting signal. TGM2 catalyses cross-linking of proteins,
demonstrates G-protein function in receptor signalling
[37] and was recently reported to phosphorylate IGFB3
[38]. IGFB3 in turn has a major role in regulation of pro-
liferation as a growth inhibitor through IGF2 binding and
alternative IGF2 independent pathways [39]. Thus impli-
cating potential regulatory functions of TGM2 in prolifer-
ation and differentiation. Surprisingly, ErbB3, which
promotes proliferation through the Wnt signalling path-
way, was also up-regulated. RT-PCR could confirm the
induction (Caco-2, 12 hrs) and a study investigating spon-
taneous Caco-2 differentiation is also in agreement with
our data on up-regulation [11]. In contrast, a recent pub-
lication reported its up-regulation in breast cancer [40],
suggesting a dual role of ERBB3 in cell cycle regulation.
The induction of MMP9, confirmed by RT-PCR (48 h
NHEK) is in additional contrast to our observations of
NAC-induced cell differentiation and proliferation.
MMP9 has been associated with angiogenesis, tumour
progression and metastasis as mediated through
degradation of the extracellular matrix (ECM) [41] and
stimulation of hyperproliferation [42]. However, tumours
with low levels of MMP9 were found to be less differenti-
ated. Thus, although MMP9 stimulates proliferation, it is
also implied in positive regulation of differentiation [42].
NAC has been proposed to inhibit activation of latent
MMP9 protein in ECM reservoirs by removal of its
propeptide and by competing for the zink ion which is
necessary for enzymatic function [43]. Hence, our data
may imply that post-transcriptional regulation of MMP9
prevails over the transcriptional changes as the major con-
trol mechanism.
A large number of multiple occurring differentially
expressed transcripts were demonstrated in Caco-2,
including intestinal trefoilfactor 3 (TFF3) and Aquaporin 3
(AQP3) among others. TFF3 has been shown to have a
central role in the maintenance and repair of intestinal
mucosa [44] and upregulation is expected during differen-
tiation. Aquaporins (AQPs) are water channel proteins,
important for the transport of water and other small pro-
teins across the cell membrane [45]. AQP1 has previously
been shown to be involved in cell cycle control [46], sug-
gesting that AQP3 may also have a role in the progression
of cancer. AQP3 has been reported to be highly expressed
in several types of stratified epithelial cells in rat, includ-
ing the epidermis [47] and the differentiated cells of the
gastrointestinal tract [48]. The expression of AQP3 was
reported to be up-regulated in differentiating Caco-2 cells
[11], while expression was shown to be down-regulated in
differentiating primary keratinocytes [49]. In this study
AQP appears to have a transient behaviour in Caco-2 cells
with a repressed behaviour at initial time point and
induced pattern at later time points (confirmed by RT-
PCR), indicating a remodelling of cell membrane
constituents.
The genes repressed in Caco-2 included for example Cyclin
D1, Inhibin beta B, BMP-2 and FHL-2. The D1 cyclin is
involved in β -catenin-TCF signalling and its down-regula-
tion induce G1 arrest [50]. FHL-2 has been demonstrated
to be a coactivator of β -catenin from cyclin D and IL-8
promoters in a colon cell line [51], suggesting that repres-
sion of FHL-2 may also repress growth. Inhibin beta and
BMP-2 are members of the TGF family of genes. Inhibin
beta is an antagonist of activin A activity and consequently
represses differentiation and promotes growth [52]. BMP-
2  on the other hand, has been demonstrated both to
induce apoptosis [53] and growth inhibition/differentia-
tion [54]. In contrast, another recent study demonstratedBMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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the ability of BMP-2 to enhance the growth of tumours
[55].
Late response (single occurrence)
A vast number of additional interesting genes with poten-
tially important roles in mediation and manifestation of
the differentiated epithelial phenotype was identified as
significantly induced or repressed in a single time point.
As an example, up-regulation in NHEK after 24 hrs was
seen for transcripts encoding CDKN2B  (p15), which is
believed to be an effector of TGF-β  induced G1 arrest and
inhibition of proliferation [56], and for CDKN1C, which
is a p21 homologue and negative regulator of cell prolifer-
ation [57]. Other up-regulated genes at this time point
were the transcription factor Jun  and  BTG1.  Jun  was
recently demonstrated to be a regulator of erythroid differ-
entiation [58] and Jun B knock out mice have been shown
to develop a proliferative disease resembeling human
chronic myeloid leukemia [59]. BTG1 has been proposed
to belong to a family of antiproliferative genes [60]. Up-
regulation was also found for cadherin 13, a gene with
growth inhibitory functions that is expressed in normal
cells but not in the majority of human tumour cells of epi-
thelial origin [61]. While not identified by global tran-
script analysis, RT-PCR investigation revealed increased
levels of E-cadherin in both Caco-2 (24 hrs) and NHEK (24
and 48 hrs), this in agreement with the previously
reported immunohistochemical data [1] that showed
increased staining of E-cadherin in NAC treated cells. In
Caco-2 cells, the differentiation-related gene NDRG1,
which is expressed during differentiation and down-regu-
lated in colorectal neoplasms [62], was up-regulated at 12
hrs. This increase was also demonstrated by RT-PCR at 12,
24 and 48 hrs after NAC treatment. The induction of Cdx2
may also be a functional change, since reduced expression
of Cdx2 has been shown to be important in colon tumor-
igenesis [63]. Interestingly, in correlation with the contro-
versial results from NHEK, an up-regulation of ErbB3 was
identified in Caco-2 at 12 hrs. In addition, the oncogene
myc  was also up-regulated in contrast to the expected
decrease. The down-regulation of Cox-2 and BMP-2 was
also in concordance with NHEK data. In addition, the
TGF-β  family member BMP-4 was repressed. This corre-
lates well with our results on repressed ID-1 expression,
since both BMP-2 and -4 up-regulate ID-1 [64,65].
Hence, although induced by the same mechanism (NAC)
and yielding the same end-stage of growth inhibition and
differentiation, the processes in NHEK and Caco-2 are on
the whole quite different. This is demonstrated by gene
specific differences that result in lack of correlation
between cell types at the same time point after treatment
as identified by cluster analysis. This is furthermore sup-
ported by the Gene Ontology analysis, tables 4 and 5,
indicating that the two cell lines achieve their differenti-
ated states using two distinct mechanisms, this in con-
cordance with previously observed effects of NAC
treatment on cell morphology and growth arrest [1]. It
should be noted that apoptosis does not appear to act as
a regulating mechanism, since only a very small propor-
tion of apoptotic genes are affected in either direction (2
to 12 genes out of 317, in either direction). This is also
supported by the previous study [1], which analysed
apoptosis by propidium iodide labelling and flow
cytometry.
As additional testimony to the lineage specific differentia-
tion programs, only very few genes were identified as
being similarly regulated in both cell-types. These
included ID-1, AQP3 and ErbB3 (as described above). Cox-
2  was also similarly down-regulated in both cell types
after NAC treatment. When investigating Cox-2 expression
by RT-PCR we could confirm the down-regulation at 24
hrs in Caco-2 and identify an additional repression in
NHEK at 1, 3 and 48 hrs after NAC treatment.
Overexpression of Cox-2 has been shown to promote cell
migration and invasion in Caco-2 cells [66] and to regu-
late colon carcinoma induced angiogenesis by production
of angiogenic factors [67]. In addition, epidermal differ-
entiation is also affected by Cox-2 over expression. Cox-2
seems to prevent entrance into the postmitotic state,
which is coupled to the switching on expression of differ-
entiation-associated proteins, allowing keratinocytes to
proliferate [68]. In correlation with our data, a NAC medi-
ated inhibition of Cox-2 expression have previously been
demonstrated in colorectal cancer [69]. Hence, it is likely
that Cox-2 repression is a NAC specific event endorsing
differentiation/growth arrest in both NHEK and Caco-2.
HBP1 was also up-regulated in both Caco-2 and NHEK
after 12 h of NAC treatment and RT-PCR could confirm an
increase in Caco-2 at 12 and 24 hrs. This corresponds to
previous findings, where HBP1 has been seen to have a
negative effect on tumours. It has previously been estab-
lished that HBP1 is a target of the retinoblastoma path-
ways [70,71] and that HBP1 negatively regulates Wnt/β -
catenin, thus inhibiting proliferation and suggesting that
HBP1 may have a tumour suppressor function [72]. Two
additional proteins, putative 28 kDa protein and proline rich
nuclear receptor coactivator-1 (PNRC1), were also identified
as differentially expressed in both cell types. RT-PCR anal-
ysis was able to confirm an up-regulation of PNRC1 in
Caco-2 24 hrs after treatment. However, these genes are
not previously described and potential functions remain
unresolved.
A proportion of the differentially expressed transcripts
were not possible to predict as being part of the differen-
tiation context. For example, ErbB3, fos, TGFβ I and myc
were found to be expressed at higher levels in differenti-BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
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ated cells, in contrast to their roles in promotion of prolif-
eration. Interestingly, a similar contrasting increase in fos
and ErbB3 levels was found in normal colonic cells as
compared to colorectal cancers in a SAGE study [73]. It is
important to note that spontaneous morphological and
functional differentiation in Caco-2 have been demon-
strated not to be coupled, with independent mosaic pat-
terns of proliferating and differentiated cells present
adjacent in the cell culture [74], which may in part explain
some of the contrasting results. However, many of the
detected differentially expressed genes in this study have
previously been described as altered in differentiated epi-
thelial cells. In NHEK cells we could for example confirm
the expected increased expression of SPRR1B  and
SPRR2A. In Caco-2 the up-regulation of AQP3, NDRG1
and TFF3 were among the genes that validated the results
from the global transcription profile analysis.
Interestingly, several genes with major relevance in psoria-
sis have been found differentially expressed as a conse-
quence of NAC treatment in the particular epithelial cells
included in this study, for example S100A9, ID-1 and Cox-
2. These findings could give a mechanistic background to
the ongoing clinical studies being carried out based on
empirical NAC treatment of patients having psoriasis.
Alternative NAC signalling mechanisms at the level of
proteins and metabolites may also be important. For
instance the phospholipid modulator, platelet activating
factor, has been demonstrated to induce differentiation
and inhibit proliferation in colon cells [75], and inhibit
proliferation in cultured human keratinocytes [76].
Accordingly, we are performing supplementary proteome
and metabolome studies. In addition, analyses of addi-
tional cell lines for finding a common pathway of molec-
ular changes that result from NAC induced differentiation
are being considered.
Conclusion
Our data demonstrate that NAC stimulated differentia-
tion induces a limited and transient early transcriptional
change, followed by a more constitutive and extensively
different expression at later time points in both NHEK
and Caco-2 cells. The genes affected are to a large extent
related to inhibition of proliferation and stimulation of
differentiation, but the responses are almost completely
lineage specific. This and further analysis of NAC medi-
ated expression changes provide a description of the com-
plex molecular mechanisms of sulphydryl reductant
treatment and potential targets for the development of
new drugs for treatment of proliferation related epithelial
disorders.
List of abbreviations
Inhibitor of differentiation 1 (ID-1)
N-acetyl-L-cysteine (NAC)
Normal human epidermal keratinocytes (NHEK)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Transferrin receptor (TFR)
Fibronectin (FN1)
Plasminogen activator inhibitor-1 (PAI1)
Regulated in development and DNA damage response 1
(REDD1),
Squamous cell carcinoma antigen 1 (SCCA1)
Highly expressed in cancer (HEC)
Stratum corneum chymotryptic enzyme (SCCE)
Melanoma growth stimulatory activity (MGSA)
Topoisomerase II (TOP2)
Transglutaminase 2 (TGM2)
Matrix metalloproteinase 9 (MMP-9)
Intestinal trefoilfactor 3 (TFF3)
Aquaporin 3 (AQP3)
Proline rich nuclear receptor coactivator-1 (PNRC1)
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
ACG participated in the design of the study, drafted the
manuscript, coordinated and carried out real-time kinetic
PCR and Affymetrix experiments as well as performed ini-
tial data processing and data analysis. IK performed data
processing, statistical analysis and data analysis as well as
assisted with the manuscript. EER performed real-time
kinetic PCRs and assisted in drafting the manuscript. LBL,
GG and EKK cultured cells and isolated totRNA. JL, TP, TL
and MCR directed the teams that carried out this study.BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
Page 17 of 19
(page number not for citation purposes)
Additional material
Acknowledgements
We kindly acknowledge The Knut and Alice Wallenberg Foundation, the 
Swedish Research Council, the Wallenberg Consortium North (WCN) for 
financial support, and the Nactilus AB, Malmö, Sweden (to LB-L, GG, EKK, 
TP).
References
1. Parasassi T, Brunelli R, Bracci-Laudiero L, Greco G, Gustafsson AC,
Krasnowska EK, Lundeberg J, Lundeberg T, Pittaluga E, Romano MC,
Serafino A: Differentiation of normal and cancer cells induced
by sulfhydryl reduction: biochemical and molecular
mechanisms.  Cell Death Differ 2005.
2. Delie F, Rubas W: A human colonic cell line sharing similarities
with enterocytes as a model to examine oral absorption:
advantages and limitations of the Caco-2 model.  Crit Rev Ther
Drug Carrier Syst 1997, 14:221-286.
3. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA: Iden-
tifying biological themes within lists of genes with EASE.
Genome Biol 2003, 4:R70.
4. De Flora S, Izzotti A, D'Agostini F, Balansky RM: Mechanisms of N-
acetylcysteine in the prevention of DNA damage and cancer,
with special reference to smoking-related end-points.  Car-
cinogenesis 2001, 22:999-1013.
5. Rosati E, Sabatini R, Ayroldi E, Tabilio A, Bartoli A, Bruscoli S,
Simoncelli C, Rossi R, Marconi P: Apoptosis of human primary B
lymphocytes is inhibited by N-acetyl-L-cysteine.  J Leukoc Biol
2004, 76:152-161.
6. Hart AM, Terenghi G, Kellerth JO, Wiberg M: Sensory neuropro-
tection, mitochondrial preservation, and therapeutic poten-
tial of n-acetyl-cysteine after nerve injury.  Neuroscience 2004,
125:91-101.
7. Rhoden CR, Lawrence J, Godleski JJ, Gonzalez-Flecha B: N-acetyl-
cysteine prevents lung inflammation after short-term inhala-
tion exposure to concentrated ambient particles.  Toxicol Sci
2004, 79:296-303.
8. Estensen RD, Levy M, Klopp SJ, Galbraith AR, Mandel JS, Blomquist
JA, Wattenberg LW: N-acetylcysteine suppression of the prolif-
erative index in the colon of patients with previous adenom-
atous colonic polyps.  Cancer Lett 1999, 147:109-114.
9. Tadjali M, Seidelin JB, Olsen J, Troelsen JT: Transcriptome
changes during intestinal cell differentiation.  Biochim Biophys
Acta 2002, 1589:160-167.
10. Mariadason JM, Arango D, Corner GA, Aranes MJ, Hotchkiss KA,
Yang W, Augenlicht LH: A gene expression profile that defines
colon cell maturation in vitro.  Cancer Res 2002, 62:4791-4804.
11. Fleet JC, Wang L, Vitek O, Craig BA, Edenberg HJ: Gene expression
profiling of Caco-2 BBe cells suggests a role for specific sign-
aling pathways during intestinal differentiation.  Physiol
Genomics 2003, 13:57-68.
12. Sun XH, Copeland NG, Jenkins NA, Baltimore D: Id proteins Id1
and Id2 selectively inhibit DNA binding by one class of helix-
loop-helix proteins.  Mol Cell Biol 1991, 11:5603-5611.
13. Hara E, Yamaguchi T, Nojima H, Ide T, Campisi J, Okayama H, Oda
K:  Id-related genes encoding helix-loop-helix proteins are
required for G1 progression and are repressed in senescent
human fibroblasts.  J Biol Chem 1994, 269:2139-2145.
14. Sun XH: Constitutive expression of the Id1 gene impairs
mouse B cell development.  Cell 1994, 79:893-900.
15. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y,
Sharrocks AD, Peters G, Hara E: Opposing effects of Ets and Id
proteins on p16INK4a expression during cellular senescence.
Nature 2001, 409:1067-1070.
16. Bjorntorp E, Parsa R, Thornemo M, Wennberg AM, Lindahl A: The
helix-loop-helix transcription factor Id1 is highly expressed
in psoriatic involved skin.  Acta Derm Venereol 2003, 83:403-409.
17. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD:
Cell cycle blockade and differentiation of ovarian cancer cells
by the histone deacetylase inhibitor trichostatin A are asso-
ciated with changes in p21, Rb, and Id proteins.  Mol Cancer
Ther 2002, 1:1181-1190.
18. Ezura Y, Tournay O, Nifuji A, Noda M: Identification of a novel
suppressive vitamin D response sequence in the 5'-flanking
region of the murine Id1 gene.  J Biol Chem 1997,
272:29865-29872.
19. Tournay O, Benezra R: Transcription of the dominant-negative
helix-loop-helix protein Id1 is regulated by a protein com-
plex containing the immediate-early response gene Egr-1.
Mol Cell Biol 1996, 16:2418-2430.
20. Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D: The tran-
scription factor EGR-1 suppresses transformation of human
fibrosarcoma HT1080 cells by coordinated induction of
transforming growth factor-beta1, fibronectin, and plas-
minogen activator inhibitor-1.  J Biol Chem 1999, 274:4400-4411.
21. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda
K, Oliner JD, McKeon F, Haber DA: REDD1, a developmentally
regulated transcriptional target of p63 and p53, links p63 to
regulation of reactive oxygen species.  Mol Cell 2002,
10:995-1005.
22. Suminami Y, Nagashima S, Murakami A, Nawata S, Gondo T,
Hirakawa H, Numa F, Silverman GA, Kato H: Suppression of a
squamous cell carcinoma (SCC)-related serpin, SCC anti-
gen, inhibits tumor growth with increased intratumor infil-
tration of natural killer cells.  Cancer Res 2001, 61:1776-1780.
23. Chen Y, Riley DJ, Chen PL, Lee WH: HEC, a novel nuclear pro-
tein rich in leucine heptad repeats specifically involved in
mitosis.  Mol Cell Biol 1997, 17:6049-6056.
24. Semprini S, Capon F, Tacconelli A, Giardina E, Orecchia A, Mingarelli
R, Gobello T, Zambruno G, Botta A, Fabrizi G, Novelli G: Evidence
for differential S100 gene over-expression in psoriatic
patients from genetically heterogeneous pedigrees.  Hum
Genet 2002, 111:310-313.
25. Yousef GM, Diamandis EP: Tissue kallikreins: new players in nor-
mal and abnormal cell growth?  Thromb Haemost 2003, 90:7-16.
26. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A:
Expression analysis of the human kallikrein 7 (KLK7) in
breast tumors: a new potential biomarker for prognosis of
breast carcinoma.  Thromb Haemost 2004, 91:180-186.
27. McGowan CH, Russell P: Human Wee1 kinase inhibits cell divi-
sion by phosphorylating p34cdc2 exclusively on Tyr15.  Embo
J 1993, 12:75-85.
Additional File 1
Summary of the top 10 differentially expressed genes in Caco-2, at all time 
points studied.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-5-75-S1.doc]
Additional File 2
Summary of the top 10 differentially expressed genes in NHEK, at all time 
points studied.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-5-75-S2.doc]
Additional File 3
All differentially expressed transcripts in NHEK at all time points.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-5-75-S3.xls]
Additional File 4
All differentially expressed transcripts in Caco-2 at all time points.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-5-75-S4.xls]BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
Page 18 of 19
(page number not for citation purposes)
28. Sonoyama K, Rutatip S, Kasai T: Gene expression of activin,
activin receptors, and follistatin in intestinal epithelial cells.
Am J Physiol Gastrointest Liver Physiol 2000, 278:G89-97.
29. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY: Regulation of cell pro-
liferation, apoptosis, and carcinogenesis by activin.  Exp Biol
Med (Maywood) 2002, 227:75-87.
30. Murata M, Eto Y, Shibai H, Sakai M, Muramatsu M: Erythroid differ-
entiation factor is encoded by the same mRNA as that of the
inhibin beta A chain.  Proc Natl Acad Sci U S A 1988, 85:2434-2438.
31. Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee
J, Orringer MB, Misek DE, Hanash SM, et al.:  The hepatocyte
nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chro-
mosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas.  Cancer Res 2002,
62:5273-5279.
32. Horuk R, Yansura DG, Reilly D, Spencer S, Bourell J, Henzel W, Rice
G, Unemori E: Purification, receptor binding analysis, and bio-
logical characterization of human melanoma growth stimu-
lating activity (MGSA). Evidence for a novel MGSA receptor.
J Biol Chem 1993, 268:541-546.
33. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW,
Yansura D, Abadi N, Raab H, Lewis GD, et al.: Identification of
heregulin, a specific activator of p185erbB2.  Science 1992,
256:1205-1210.
34. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR, Wil-
liams RS: Cdc6 is regulated by E2F and is essential for DNA
replication in mammalian cells.  Proc Natl Acad Sci U S A 1998,
95:3603-3608.
35. Grdina DJ, Murley JS, Roberts JC: Effects of thiols on topoisomer-
ase-II alpha activity and cell cycle progression.  Cell Prolif 1998,
31:217-229.
36. Mondal N, Parvin JD: DNA topoisomerase IIalpha is required
for RNA polymerase II transcription on chromatin
templates.  Nature 2001, 413:435-438.
37. Fesus L, Piacentini M: Transglutaminase 2: an enigmatic
enzyme with diverse functions.  Trends Biochem Sci 2002,
27:534-539.
38. Mishra S, Murphy LJ: Tissue transglutaminase has intrinsic
kinase activity: Identification of transglutaminase 2 as an
insulin-like growth factor binding protein-3 kinase.  J Biol Chem
2004, 279(23):23863-8.
39. Ricort JM, Binoux M: Insulin-like growth factor-binding protein-
3 activates a phosphotyrosine phosphatase. Effects on the
insulin-like growth factor signaling pathway.  J Biol Chem 2002,
277:19448-19454.
40. Perez-Nadales E, Lloyd AC: Essential function for ErbB3 in
breast cancer proliferation.  Breast Cancer Res 2004, 6:137-139.
41. Ray JM, Stetler-Stevenson WG: The role of matrix metallopro-
teases and their inhibitors in tumour invasion, metastasis
and angiogenesis.  Eur Respir J 1994, 7:2062-2072.
42. Coussens LM, Werb Z: Matrix metalloproteinases and the
development of cancer.  Chem Biol 1996, 3:895-904.
43. Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G, D'Ago-
stini F, De Flora S, Noonan DM, Albini A: N-acetylcysteine inhibits
endothelial cell invasion and angiogenesis.  Lab Invest 1999,
79:1151-1159.
44. Mashimo H, Wu DC, Podolsky DK, Fishman MC: Impaired defense
of intestinal mucosa in mice lacking intestinal trefoil factor.
Science 1996, 274:262-265.
45. Agre P, Brown D, Nielsen S: Aquaporin water channels: unan-
swered questions and unresolved controversies.  Curr Opin Cell
Biol 1995, 7:472-483.
46. Delporte C, Chen ZJ, Baum BJ: Aquaporin 1 expression during
the cell cycle in A5 cells.  Biochem Biophys Res Commun 1996,
228:223-228.
47. Matsuzaki T, Suzuki T, Koyama H, Tanaka S, Takata K: Water chan-
nel protein AQP3 is present in epithelia exposed to the envi-
ronment of possible water loss.  J Histochem Cytochem 1999,
47:1275-1286.
48. Koyama Y, Yamamoto T, Tani T, Nihei K, Kondo D, Funaki H, Yaoita
E, Kawasaki K, Sato N, Hatakeyama K, Kihara I: Expression and
localization of aquaporins in rat gastrointestinal tract.  Am J
Physiol 1999, 276:C621-627.
49. Zheng X, Bollinger Bollag W: Aquaporin 3 colocates with phos-
pholipase d2 in caveolin-rich membrane microdomains and
is downregulated upon keratinocyte differentiation.  J Invest
Dermatol 2003, 121:1487-1495.
50. Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kow-
alik T, Groden J: The APC tumor suppressor controls entry
into S-phase through its ability to regulate the cyclin D/RB
pathway.  Gastroenterology 2002, 123:751-763.
51. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X,
Flajolet M, Prigent S, Buendia MA: Identification of the LIM pro-
tein FHL2 as a coactivator of beta-catenin.  J Biol Chem 2003,
278:5188-5194.
52. Bernard DJ, Chapman SC, Woodruff TK: Mechanisms of inhibin
signal transduction.  Recent Prog Horm Res 2001, 56:417-450.
53. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR,
Overland RP, Strand AD, Tapscott SJ, Olson JM: BMP-2 mediates
retinoid-induced apoptosis in medulloblastoma cells through
a paracrine effect.  Nat Med 2003, 9:1033-1038.
54. Wen XZ, Miyake S, Akiyama Y, Yuasa Y: BMP-2 modulates the
proliferation and differentiation of normal and cancerous
gastric cells.  Biochem Biophys Res Commun 2004, 316:100-106.
55. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Lan-
genfeld J: The mature bone morphogenetic protein-2 is aber-
rantly expressed in non-small cell lung carcinomas and
stimulates tumor growth of A549 cells.  Carcinogenesis 2003,
24:1445-1454.
56. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-
beta-induced cell cycle arrest.  Nature 1994, 371:257-261.
57. Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-
dependent kinase inhibitor with unique domain structure
and tissue distribution.  Genes Dev 1995, 9:639-649.
58. Jacobs-Helber SM, Abutin RM, Tian C, Bondurant M, Wickrema A,
Sawyer ST: Role of JunB in erythroid differentiation.  J Biol Chem
2002, 277:4859-4866.
59. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wag-
ner EF: Chronic myeloid leukemia with increased granulocyte
progenitors in mice lacking junB expression in the myeloid
lineage.  Cell 2001, 104:21-32.
60. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L,
Garoccio M, Germain D, Samarut J, Magaud JP: BTG1, a member
of a new family of antiproliferative genes.  Embo J 1992,
11:1663-1670.
61. Lee SW: H-cadherin, a novel cadherin with growth inhibitory
functions and diminished expression in human breast
cancer.  Nat Med 1996, 2:776-782.
62. van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made
AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT: A novel gene
which is up-regulated during colon epithelial cell differentia-
tion and down-regulated in colorectal neoplasms.  Lab Invest
1997, 77:85-92.
63. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM: Colonic poly-
posis caused by mTOR-mediated chromosomal instability in
Apc+/Delta716 Cdx2+/- compound mutant mice.  Nat Genet
2003, 35:323-330.
64. Shepherd TG, Nachtigal MW: Identification of a putative auto-
crine bone morphogenetic protein-signaling pathway in
human ovarian surface epithelium and ovarian cancer cells.
Endocrinology 2003, 144:3306-3314.
65. Langenfeld EM, Langenfeld J: Bone morphogenetic protein-2
stimulates angiogenesis in developing tumors.  Mol Cancer Res
2004, 2:141-149.
66. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in
human colon cancer cells increases metastatic potential.
Proc Natl Acad Sci U S A 1997, 94:3336-3340.
67. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN:
Cyclooxygenase regulates angiogenesis induced by colon
cancer cells.  Cell 1998, 93:705-716.
68. Neufang G, Furstenberger G, Heidt M, Marks F, Muller-Decker K:
Abnormal differentiation of epidermis in transgenic mice
constitutively expressing cyclooxygenase-2 in skin.  Proc Natl
Acad Sci U S A 2001, 98:7629-7634.
69. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow
JD: Antioxidants reduce cyclooxygenase-2 expression, pros-
taglandin production, and proliferation in colorectal cancer
cells.  Cancer Res 1998, 58:2323-2327.
70. Lavender P, Vandel L, Bannister AJ, Kouzarides T: The HMG-box
transcription factor HBP1 is targeted by the pocket proteins
and E1A.  Oncogene 1997, 14:2721-2728.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:75 http://www.biomedcentral.com/1471-2407/5/75
Page 19 of 19
(page number not for citation purposes)
71. Tevosian SG, Shih HH, Mendelson KG, Sheppard KA, Paulson KE, Yee
AS: HBP1: a HMG box transcriptional repressor that is tar-
geted by the retinoblastoma family.  Genes Dev 1997,
11:383-396.
72. Sampson EM, Haque ZK, Ku MC, Tevosian SG, Albanese C, Pestell
RG, Paulson KE, Yee AS: Negative regulation of the Wnt-beta-
catenin pathway by the transcriptional repressor HBP1.
Embo J 2001, 20:4500-4511.
73. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR,
Vogelstein B, Kinzler KW: Gene expression profiles in normal
and cancer cells.  Science 1997, 276:1268-1272.
74. Vachon PH, Beaulieu JF: Transient mosaic patterns of morpho-
logical and functional differentiation in the Caco-2 cell line.
Gastroenterology 1992, 103:414-423.
75. Wang H, Chakrabarty S: Platelet-activating factor activates
mitogen-activated protein kinases, inhibits proliferation,
induces differentiation and suppresses the malignant pheno-
type of human colon carcinoma cells.  Oncogene 2003,
22:2186-2191.
76. Shimada A, Ota Y, Sugiyama Y, Sato S, Kume K, Shimizu T, Inoue S:
In situ expression of platelet-activating factor (PAF)-recep-
tor gene in rat skin and effects of PAF on proliferation and
differentiation of cultured human keratinocytes.  J Invest
Dermatol 1998, 110:889-893.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/75/prepub